#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Ovarian cancer Dementia Alzheimer's type Colorectal cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Malignant melanoma Non-small cell lung cancer metastatic Asthma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fatty acid oxidation disorder Cortical dysplasia Hypereosinophilic syndrome Mucopolysaccharidosis I Langerhans cell sarcoma Ischaemic stroke Meningococcal immunisation C3 glomerulopathy Multifocal motor neuropathy Marfan's syndrome Adenovirus infection Breast cancer Anti-neutrophil cytoplasmic antibody positive vasculitis Fibrosarcoma Adrenogenital syndrome More trials…

    Learn about Rare Diseases

    Wiskott-Aldrich syndrome – Life with Disease Kearns-Sayre syndrome – Treatment Adrenogenital syndrome – Treatment Mucous membrane pemphigoid – Life with Disease Haemolytic uraemic syndrome – Diagnostics Lymphangiosarcoma – Diagnostics Mucopolysaccharidosis I Undifferentiated sarcoma – Life with Disease Breast angiosarcoma metastatic – Life with Disease Rosai-Dorfman syndrome – Trials in Disease More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Padeliporfin Imiquimod Clavulanic Acid Damoctocog Alfa Pegol Methylprednisolone Florbetapir (18F) Human Albumin Solution Satralizumab 64CU-PSMA I&T Anidulafungin Sym024 Doxycycline Hyclate Alks 2680 TUVATEXIB Clomifene Citrate Verapamil Hydrochloride Oregovomab Hydroxocobalamin Pelareorep Sodium Nitroprusside Dihydrate More therapies…

    Learn about Your Condition

    Myxofibrosarcoma Petit mal epilepsy Food allergy Congenital aplastic anaemia Arthroscopy Blood disorder High-grade B-cell lymphoma Adenocarcinoma of colon Retroperitoneal fibrosis Cachexia Anal cancer Extraskeletal ossification Pulmonary sarcoidosis Obsessive-compulsive disorder Thyroid cancer metastatic More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Koranyi National Institute For Pulmonology

Koranyi National Institute For Pulmonology

Koranyi Frigyes Ut 1, Budapest, 1121, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Small cell lung cancer extensive stage
    Investigated drugs:
    • Infliximab
    • Carboplatin
    • Durvalumab
    Austria Belgium Denmark France Germany Greece +7

  • Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

    Recruiting

    3 1
    Investigated drugs:
    • Bi 1291583
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1
    Investigated drugs:
    • Adagrasib
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Croatia France Germany +9

  • Study on Tozorakimab for Adults with Uncontrolled Asthma Using Medium-to-High Dose Inhaled Corticosteroids

    Recruiting

    2 1 1
    Investigated diseases:
    • Asthma
    Investigated drugs:
    • Salbutamol Sulfate
    • Tozorakimab
    France Greece Hungary Italy Spain

  • Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

    Recruiting

    3 1
    Investigated diseases:
    • Acute respiratory failure
    Investigated drugs:
    • Tozorakimab
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study comparing Rilvegostomig plus chemotherapy versus Pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

    Recruiting

    3 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer
    Investigated drugs:
    • Infliximab
    • Carboplatin
    • Cisplatin
    Belgium France Germany Hungary Italy The Netherlands +2

  • Study of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated diseases:
    • Non-small cell lung cancer stage II
    • Non-small cell lung cancer stage III
    Investigated drugs:
    • Iph5201
    • Carboplatin
    • Cisplatin
    France Greece Hungary Poland

  • Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

    Recruiting

    2 1 1
    Investigated drugs:
    • Repotrectinib
    Belgium Denmark France Germany Hungary Italy +3

  • Study on APL-101 for Treating Advanced Solid Tumors and Non-Small Cell Lung Cancer with MET Changes in Patients

    Recruiting

    1 1 1
    Investigated diseases:
    • Central nervous system neoplasm
    • Non-small cell lung cancer
    Investigated drugs:
    • Apl-101
    France Hungary Italy Spain

  • Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    • Buclizine Hydrochloride
    • Carboplatin
    • Codeine Phosphate
    Austria Czechia France Germany Hungary Ireland +4
Previous Page
1 2 3 4 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!